1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medi&Gene Inc. currently manages 1 pending office action. This action is assigned to ORWIG, KEVIN S, who is the busiest examiner with 1 pending case. The portfolio involves 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company's filings are being reviewed by a single official within a specific administrative group.
The involvement of 1 distinct art unit indicates that the company's filings are being reviewed within a single specialized group. With 1 pending office action, the prosecution activity is currently focused on one active case. ORWIG, KEVIN S, as the 1 distinct examiner, is the only official currently reviewing the company's pending applications. Practitioners should focus their strategy on this 1 distinct examiner, as the outcome of the 1 pending office action depends entirely on his review. This focused environment allows for a direct prosecution approach without the need to manage multiple examiner perspectives across the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574406 | PEPTIDE HAVING ANTIDIABETIC ACTIVITY AND USE THEREOF | ORWIG, KEVIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574406 | PEPTIDE HAVING ANTIDIABETIC ACTIVITY AND USE THEREOF | ORWIG, KEVIN S | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574406 | PEPTIDE HAVING ANTIDIABETIC ACTIVITY AND USE THEREOF | ORWIG, KEVIN S | 3991 | DP | Final Rejection | — | Pending | Dec 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedi&Gene Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kevin S Orwig has the most, with 1 of Medi&Gene Inc.'s pending office actions.
